Espervita is a startup based in the United States.
Espervita Therapeutics develops first-in-class acetyl-CoA metabolic enzyme inhibitors targeting metabolic diseases such as steatohepatitis, chronic kidney disease, and liver fibrosis, with a lead compound showing efficacy in preclinical models.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.